Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Tenax Therapeutics (TENX)

(Delayed Data from NSDQ)

$3.48 USD

-0.12 (-3.33%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $3.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Tenax Therapeutics, Inc. [TENX]

Reports for Purchase

Showing records 1 - 20 ( 47 total )

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/28/2024

Pages: 6

4Q23: Phase 3 TNX-103 PH-HFpEF Program Started, May Outlicense Drug Ex- U.S.

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/20/2024

Pages: 6

Negotiates Global Levosimendan Rights, Versus Prior U.S. Canadian Rights

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

02/15/2024

Pages: 10

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

02/15/2024

Pages: 5

Raises Cash, Phase 3 Enrolling, Receives Yet Another Levosimendan Patent

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

02/13/2024

Industry Report

Pages: 5

Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/13/2023

Pages: 5

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/13/2023

Pages: 5

FDA Clears TNX-103 Phase 3s In PHHFpEF, 6MWD As 1EP, No CVOT Required

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

07/20/2023

Pages: 10

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

07/20/2023

Pages: 5

USPTO Issues Use Patent for Oral Levosimendan (TNX-103) in PH-HFpEF

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

06/01/2023

Pages: 12

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

06/01/2023

Pages: 5

USPTO Grants Notice of Allowance for

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

04/03/2023

Pages: 5

Focused On Oral Levosimendan In PHHFpEF, Pivotal Trial starting in 2023

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

03/24/2023

Pages: 9

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/24/2023

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/23/2023

Pages: 6

Patent Issuance For IV Levosimendan in PH-HFpEF Bodes Well For TNX-103

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/07/2023

Pages: 7

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

03/07/2023

Pages: 35

Phase 3-Ready Assets to Address Different Types of Pulmonary Hypertension -Initiating Coverage

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 35.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/14/2022

Pages: 4

Levosimendans Significant Market Potential Remains Underappreciated; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/17/2022

Pages: 4

TNX-201 IMPROVE Phase 3 Trial in PAH on Track for 2H22; Reiterate Buy Rating and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Tenax Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/26/2021

Pages: 4

Two Registration-Enabling Studies in the Queue for 2022; Reiterate Buy Rating and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

previous
1
2
3
next